Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma 12Leukemia 12Neuroblastoma 8Multiple Myeloma 6Myelodysplastic Syndromes 5Central Nervous System Neoplasms 5Brain Neoplasms 5Lymphoma, Follicular 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Teratoma 3Neoplasms, Plasma Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Monocytic, Acute 3Immunoglobulin Light-chain Amyloidosis 3Congenital Abnormalities 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Recurrence 2Preleukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Neoplasms 2Myeloproliferative Disorders 2Lymphoproliferative Disorders 2

Interventions

Amifostine 4Cisplatin 3Radiotherapy 2Paclitaxel 2Filgrastim 2Carboplatin 2Peripheral Blood Stem Cell Transplantation 1Octreotide 1Melphalan 1Furosemide 1Etoposide 1Erythropoietin 1Epoetin Alfa 1Duloxetine Hydrochloride 1Brachytherapy 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Drug-Related Side Effects and Adverse Reactions × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡